Date: 20 April 2023
The RACGP has written to the Pharmaceutical Benefits Advisory Committee (PBAC) seeking clarity on recent changes by PBAC to the General Schedule (Section 85) listing, population criteria and treatment criteria for fluticasone propionate 50 microgram indicated for the prophylactic management of asthma. The RACGP is seeking clarification of PBAC’s reasons for this decision and has highlighted concerns with equity of access, clinical risk in delaying initiation of this medication, significant health and/or mortality risk from substitution with other medicines and broader costs to the health system of otherwise unnecessary consultations with paediatric respiratory physicians and paediatricians.
Read the submission
RACGP letter to PBAC Re: Changes to Fluticasone Propionate 50mcg (PDF)